Gilead Sciences (GILD)

Changes in a federal healthcare authority could negatively impact one of the company's important businesses.

The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting pre-exposure prophylaxis, BMO said.

Visa, which will report third quarter results on Tuesday, July 29, is analyst Stephanie Link's final trade.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval from a key European regulatory committee. 

Gilead stock is flashing "buy" in bright green letters.

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates.

Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.

GILEAD SCIENCES INC (NASDAQ:GILD) appears undervalued with strong profitability and reasonable financial health, making it a potential candidate for value investors.

Bill Gates raises concerns over U.S. aid cuts' impact on HIV programs in Africa and calls for a reversal of the decision.

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year.

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding uncertainty.

Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three years in countries supported by the Global Fund, at no profit to the company.